A phase i trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood

Kenneth J. Cohen, Iris C. Gibbs, Paul G. Fisher, Robert J. Hayashi, Margaret E. MacY, Lia Gore

Research output: Contribution to journalArticlepeer-review

Abstract

BackgroundArsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.MethodsWe conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.ResultsATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.ConclusionsThe recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.

Original languageEnglish (US)
Pages (from-to)783-787
Number of pages5
JournalNeuro-oncology
Volume15
Issue number6
DOIs
StatePublished - Jun 2013

Keywords

  • arsenic trioxide
  • astrocytoma
  • chemoradiotherapy
  • pediatrics

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase i trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood'. Together they form a unique fingerprint.

Cite this